Based on these findings, one could speculate that DMARD-treatment in the CSA-phase may diminish the burden of fatigue more effectively compared to the effect of DMARDs in classified RA, especially in ACPA-positive patients; though this remains a subject for future research. Here, PRTN3 is linked to rheumatoid arthritis.